Nephritis

Merck Serono announced that its U.S. affiliate EMD Serono has signed a research agreement with Pfizer Inc. and the Broad Institute in Cambridge, Massachusetts, U.S. The collaboration is focused on the genomic profiling of Systemic Lupus Erythematosus (SLE) and Lupus Nephritis (LN) patients. The rese more

Vifor Pharma, the pharma business sector of the Galenica Group, and Roche announced that the maintenance phase of the Aspreva Lupus Management Study (ALMS) has successfully achieved its primary endpoint. The trial demonstrates the superiority of Roche’s CellCept (mycophenolate mofetil) versus azathi more

Investigators have identified a new disease mechanism and therapeutic approach for a type of advanced kidney disease that is a common cause of complications in patients with lupus. The study was led by investigators at Hospital for Special Surgery and appears in Proceedings of the National Academy o more

Systemic Lupus Erythematosus (SLE) is a chronic systemic inflammatory disease. Autoantibodies (autoAbs) against double‐stranded DNA (ds DNA), the hallmark of lupus, are produced and maintained by the interaction between auto‐reactive B cells and CD4+ T cells. This interplay is controlled by the CD more

Aim: The objective of this study was to identify the association between genotypes of miR-146a rs2910164 and expression of TRAF6 as well as the risk of lupus nephritis (LN). Results: A total of 567 systemic lupus erythematosus patients both with and without LN were included in the study. The lucifer more

Renal infiltration of inflammatory cells contributes to the pathogenesis of Lupus nephritis (LN). Current knowledge on the recruitment mechanisms relies mainly on findings in rodent models. Here, we assess various chemokine pathways in human LN by comparing urinary chemokine concentrations (in 25 more